US 12,480,118 B2
Treatment of Fuchs' endothelial corneal dystrophy
Venkateswara V. Mootha, Coppell, TX (US)
Assigned to The Board of Regents of The University of Texas System, Austin, TX (US)
Filed by The Board of Regents of The University of Texas System, Austin, TX (US)
Filed on Nov. 8, 2022, as Appl. No. 18/053,559.
Application 18/053,559 is a continuation of application No. 16/492,522, granted, now 11,512,312, issued on Nov. 29, 2022, previously published as PCT/US2018/021729, filed on Mar. 9, 2018.
Claims priority of provisional application 62/560,472, filed on Sep. 19, 2017.
Claims priority of provisional application 62/469,952, filed on Mar. 10, 2017.
Prior Publication US 2024/0002849 A1, Jan. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 31/7105 (2006.01); C12N 15/11 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 9/0048 (2013.01); A61K 31/7105 (2013.01); C12N 15/11 (2013.01); C12N 2310/11 (2013.01); C12N 2310/20 (2017.05); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3515 (2013.01)] 10 Claims
 
1. A method of treating a subject with Fuchs endothelial corneal dystrophy comprising administering a gene editing construct and two guide RNAs that target intron 2 of TCF4 or the 3′-UTR of DMPK, wherein said gene editing construct excises the CTG tract repeat.